2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

5461 Phase 1 study of loncastuximab tesirine in combination with DA-EPOCH-R in newly diagnosed aggressive B-cell lymphomas: High complete response rates but delayed toxicity

Elif Yilmaz, MD, Anjishnu Banerjee2, Joanna Zurko, MD3, Aniko Szabo, PhD4, Ashley White5, Alexander Hinman6, Carrie Herdeman7, Farrukh T Awan, M.D.M.S.,M.B.A.8, Nirav N. Shah, MD, MS9, Mehdi Hamadani, MD10
1 University of Texas Southwestern Medical School, Dallas, Texas, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 SSM Health Dean Medical Group, Madison, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 University of Texas Southwestern Medical School, Dallas, Texas, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Introduction: Patients (pts) with newly diagnosed aggressive B-cell lymphomas such as MYC-rearranged diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma not otherwise specified (HGBCL, NOS) and double/triple-hit lymphomas remain at substantial risk for relapsed/refractory (R/R) disease, despite intensive frontline chemoimmunotherapy. Loncatuximab tesirine (lonca), a CD19-directed antibody-drug conjugate, has demonstrated significant activity in R/R DLBCL, supporting its incorporation into frontline therapy. We conducted a phase I study evaluating the safety and preliminary efficacy of lonca combined with DA-EPOCH-R.

Methods: This multicenter investigator-initiated phase 1 study (NCT05270057) used a standard 3+3 dose-escalation design to evaluate three dose levels of lonca administered on day 2 of each 21-day cycle (C) together with 6 cycles of DA-EPOCH-R given in standard fashion. The dose-limiting toxicity (DLT) assessment period comprised the first 2 treatment cycles. Pts who were not evaluable for DLT assessment were replaced per protocol. Primary objectives were safety, determination of maximum tolerated dose, and recommended dose for the expansion cohort (RDE). Secondary objectives included end of treatment (EOT) overall response rate (ORR), complete response (CR), and partial response (PR) rates, as well as one-year progression-free survival (PFS) and overall survival (OS) per Lugano 2014 criteria.

Results: From April 2023 through June 2025, 13 pts were enrolled. Median follow-up was 17 months. Median age was 61 years (range, 26–80), 38% (N=5) were females, 85% (N=11) were White, 69% (N=9) had stage III-IV disease, 38% (N=5) had ECOG score of 2, 61% (N=8) had IPI ³ 3, 54% received pre-phase steroid therapy and 16% received radiation for symptom palliation prior to treatment initiation.

No DLTs were observed during the initial two cycle DLT period. Dose level (DL) 3 (0.15 mg/kg for C1–2 and 0.075 mg/kg for C3–6) was selected as RDE. Six out of 13 pts were treated at DL3: 4/6 in dose escalation and 2/6 in expansion cohorts. One pt (DL2) discontinued protocol therapy due to bowel perforation at a site previously involved by lymphoma during C1 and subsequently completed therapy off protocol without disease progression. Another pt (DL3) had spontaneous tracheal stent dislodgement unrelated to study treatment during C1 and transitioned to hospice.

Eleven pts were response evaluable. Among evaluable pts, the interim ORR after C2 was 100%, including 8/11 (72.7%) with CR and 3/11 (27.2%) with PR. At EOT, 10/11 pts (90.9%) achieved CR. The only patient with progressive disease at EOT was treated at DL1, while all pts treated at DL2 and DL3 achieved CR (100% each). One-year PFS and OS estimates were 81.8% (95% CI, 61.9%–100.0%) and 90.9% (95% CI, 75.4%–100.0%), respectively.

Grade ³ 3 hematologic treatment-emergent adverse events (TEAEs) were common across dose levels, including neutropenia in 9/13 pts (69.2%), thrombocytopenia in 10/13 pts (76.9%) and anemia in 8/13 pts (61.5%). Febrile neutropenia occurred in 5/13 pts (38.5%), 4/5 at DL3. TEAEs of special interest included 1 grade 3 pleural effusion (7.7%), 1 grade 3 pericardial effusion (7.7%) and 1 pericardial tamponade (7.7%) occurring after C6, all observed at DL3.

Although early tolerability met protocol-defined safety criteria, clinically significant delayed toxicity emerged beyond the DLT period. Among DLT evaluable pts median number of lonca doses administered was 5. Delayed dermatologic toxicity was the predominant reason for lonca discontinuation, with 4 pts discontinuing lonca early due to grade 2/3 rash occurring after cycles 3–5. One additional pt discontinued both lonca and DA-EPOCH-R after C4 due to grade 4 ALT/AST/bilirubin elevation, with features of drug-induced liver injury noted on liver biopsy. Ten out of 11 response evaluable pts completed all 6 planned cycles of DA-EPOCH-R. Because of cumulative toxicity occurring beyond the DLT window, the study was terminated during the expansion phase prior to completion of planned enrollment.

Conclusions: Despite encouraging efficacy, cumulative toxicity beyond DLT window limited treatment delivery and precluded study completion.  Alternative study designs exploring sequential/time limited approaches of lonca with chemoimmunotherapy may warrant exploration to balance the efficacy and tolerability profiles.  

Elif Yilmaz, MD: Ideology Health - Honoraria; Decera Clinical Insights - Honoraria; Curio Sciences - Honoraria; Binaytara Foundation - Honoraria; Imedex - Honoraria; BMS - Consultancy (Includes expert testimony); Pierre Fabre Pharmaceuticals - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Onviv - Consultancy (Includes expert testimony)